COVID-19 patients with more severe symptoms may develop longer-lasting immunity: study

COVID-19 patients with more severe symptoms may develop longer-lasting immunity: study
In this handout photo released by the University of Oxford blood samples from coronavirus vaccine trials are handled inside the Jenner Institute in Oxford, England Thursday June 25, 2020. (John Cairns, University of Oxford via AP)


TORONTO -- Patients with severe COVID-19 infections may be protected for longer after contracting the disease than those with mild symptoms, according to a new study.

The in the U.K. found that the immune response to COVID-19 wanes in the first three months following infection and the duration of immunity correlates to how severe the infection was.

The study found that those who experienced more severe COVID-19 infections may be protected for longer periods than patients who experience milder symptoms. Researchers say the reaction rates of the immune response are also similar to other endemic seasonal coronaviruses such as influenza.

"We show that the kinetics of the neutralizing antibody response is typical of an acute viral infection, with declining neutralizing antibody titres observed after an initial peak, and that the magnitude of this peak is dependent on disease severity," researchers wrote in the study.

The findings were published Monday in the journal Nature Microbiology.

Although people infected with SARS-CoV-2, the virus that causes COVID-19, generate an immune response to the virus, researchers behind the study wanted to gain a better understanding of how long that immune response lasts.

For three months the researchers studied the antibody response of 59 patients and 37 health-care workers at Guy s and St. Thomas NHS Foundation Trust in London who tested positive for COVID-19 and showed signs of symptoms.

While antibody responses to other endemic seasonal coronaviruses can last for as little as 12 weeks, the study reported that antibodies to COVID-19 can be detected in some individuals even 12-34 months after infection.

Typical of an acute viral infection, the study reported that the patients’ antibody response peaked at approximately one month after the onset of symptoms, before starting to decline.

Those with severe symptoms generated the strongest antibody response, and although this response diminished, neutralizing antibodies were still detectable more than 60 days after symptoms began, according to the data.

Patients with milder symptoms also generated an immune response, but the study says it was smaller and declined towards baseline levels. For example, some health-care workers had no detectable immune response within the same follow-up period.

Researchers say the findings, which provide insights into the body s response to the novel coronavirus, will have notable implications for future vaccine design and disease management.

The study noted that COVID-19 vaccines will need to generate a "robust and long-lasting immune response" similar to that generated in severely ill patients. The authors added that additional doses of the vaccine may also be necessary on a regular basis.

"The present study has important implications when considering widespread serological testing and antibody protection against reinfection with SARS-CoV-2, and may suggest that vaccine boosters are required to provide long-lasting protection," according to the study.
Read more on CTVnews
News Topics :
Similar Articles :
Being previously infected with a coronaviruses that cause the common cold may decrease the severity of severe acute respiratory syndrome coronavirus SARS CoV 2 infections, according to results of a new study....
Most newly discharged patients who recently recovered from COVID 19 produce virus specific antibodies and T cells, suggests a study published on May 3rd in the journal Immunity, but the responses of...
PARIS, FRANCE Patients who recover from coronavirus infections may lose their immunity to reinfection within months, according to research released on Monday that experts said could have...
A Seattle fishing vessel that departed port in May returned 18 days later with an unusual haul the first human evidence that neutralizing antibodies provide protection from reinfection by SARS CoV 2....
The first COVID 19 vaccine to reach phase 1 clinical trial has been found to be safe, well tolerated, and able to generate an immune response against SARS CoV 2 in humans, according to...